{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:58:48Z","timestamp":1783796328423,"version":"3.55.0"},"reference-count":41,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Astellas and MSD for conference attendance"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.2217\/fmb-2018-0119","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T14:31:00Z","timestamp":1529332260000},"page":"1283-1293","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Economic Impact of Treating Invasive Mold Disease with Isavuconazole Compared with Liposomal Amphotericin B in the UK"],"prefix":"10.1080","volume":"13","author":[{"given":"Emma","family":"Bagshaw","sequence":"first","affiliation":[{"name":"Covance Market Access,\rLondon,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Enoch","sequence":"additional","affiliation":[{"name":"Clinical Microbiology & Public Health Laboratory,Public Health England,National Infection Service, Box 236,Addenbrooke\u2018s Hospital,Cambridge University Hospitals NHS Foundation Trust,\rCambridge,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Blackney","sequence":"additional","affiliation":[{"name":"Covance Market Access,\rLondon,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Posthumus","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd,\rBasel,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kuessner","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd,\rBasel,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"e_1_3_4_3_1","article-title":"Public summary of opinion on orphan designation","author":"European Medicines Agency. Committee for Orphan Medicinal Products","year":"2014","unstructured":"European Medicines Agency. Committee for Orphan Medicinal Products . Public summary of opinion on orphan designation . Isavuconazonium sulfate for the treatment of invasive aspergillosis ( 2014 ). www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2014\/07\/WC500169890.pdf .","journal-title":"Isavuconazonium sulfate for the treatment of invasive aspergillosis"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.140087"},{"key":"e_1_3_4_5_1","article-title":"Public summary of opinion on orphan designation","author":"European Medicines Agency. Committee for Orphan Medicinal Products","year":"2014","unstructured":"European Medicines Agency. Committee for Orphan Medicinal Products . Public summary of opinion on orphan designation . Isavuconazonium sulfate for the treatment of mucormycosis ( 2014 ). www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2014\/07\/WC500169714.pdf .","journal-title":"Isavuconazonium sulfate for the treatment of mucormycosis"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku506"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-310"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/319211"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_4_10_1","unstructured":"Vfend 50 mg and 200 mg film-coated tablets Vfend 200 mg powder for solution for infusion Vfend 200 mg powder and solvent for solution for infusion Vfend 40 mg\/ml powder for oral suspension (voriconazole) summary of product characteristics . Pfizer Ltd ( 2017 ). www.medicines.org.uk\/emc\/medicine\/10059 ."},{"key":"e_1_3_4_11_1","volume-title":"Summary of product characteristics","year":"2017","unstructured":"AmBisome 50 mg powder for solution for infusion (liposomal amphotericin B) . Summary of product characteristics . Gilead Sciences Ltd. ( 2017 ). www.medicines.org.uk\/emc\/medicine\/1236 ."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.05.010"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152900"},{"key":"e_1_3_4_14_1","volume-title":"Summary of product characteristics","year":"2017","unstructured":"Noxafil 100 mg gastro-resistant tablets (posaconazole) . Summary of product characteristics . Merck Sharp & Dohme Ltd ( 2017 ). www.medicines.org.uk\/emc\/medicine\/28880 ."},{"key":"e_1_3_4_15_1","volume-title":"Summary of product characteristics","year":"2016","unstructured":"Cancidas 50 mg powder for solution for infusion (caspofungin) . Summary of product characteristics . Merck Sharp & Dohme Ltd ( 2016 ). www.medicines.org.uk\/emc\/medicine\/12843 ."},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp355"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv040"},{"key":"e_1_3_4_18_1","volume-title":"Summary of product characteristics","year":"2017","unstructured":"Cresemba 200 mg powder for concentrate for solution for infusion . Summary of product characteristics . Basilea Pharmaceutica International Ltd. ( 2017 ). www.medicines.org.uk\/emc\/medicine\/31236 ."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00944.x"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2010.01947.x"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00071-2"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.620"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097650"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/514341"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv236"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200201243460403"},{"key":"e_1_3_4_28_1","volume-title":"43rd Annual Meeting of the European Society for Blood and Bone Marrow Transplantation","author":"Herbrecht R","year":"2017","unstructured":"Herbrecht R , KuessnerD , PooleyN , PosthumusJ , EscrigE . Meta-analysis of clinical outcomes associated with isavuconazole versus relative comparators for patients with invasive aspergillosis . Presented at : 43rd Annual Meeting of the European Society for Blood and Bone Marrow Transplantation . Marseille, France , 26\u201329 March 2017 ."},{"key":"e_1_3_4_29_1","unstructured":"Inflation.eu Worldwide Inflation Data. Inflation Great Britain 2017 ( 2017 ). http:\/\/inflation.eu\/inflation-rates\/great-britain\/historic-inflation\/cpi-inflation-great-britain-2017.aspx ."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1164175"},{"key":"e_1_3_4_31_1","unstructured":"British National Formulary . Isavuconazole ( 2018 ). https:\/\/bnf.nice.org.uk\/medicinal-forms\/isavuconazole.html ."},{"key":"e_1_3_4_32_1","unstructured":"British National Formulary . Amphotericin ( 2018 ). https:\/\/bnf.nice.org.uk\/medicinal-forms\/amphotericin.html ."},{"key":"e_1_3_4_33_1","unstructured":"British National Formulary . Posaconazole ( 2018 ). https:\/\/bnf.nice.org.uk\/medicinal-forms\/posaconazole.html ."},{"key":"e_1_3_4_34_1","unstructured":"Personal Social Services Research Unit . Unit costs of health and social care 2015 ( 2016 ). www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2016\/ ."},{"key":"e_1_3_4_35_1","unstructured":"NHS reference costs 2015-16. Main schedule ( 2016 ). www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016 ."},{"key":"e_1_3_4_36_1","article-title":"Manchester","author":"Mycology Reference Centre","year":"2018","unstructured":"Mycology Reference Centre . Manchester . Antifungal assays ( 2018 ). www.mycologymanchester.org\/antifungal.php .","journal-title":"Antifungal assays"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-1112-1184"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0231"},{"key":"e_1_3_4_40_1","volume-title":"43rd Annual Meeting of the European Society for Blood and Marrow Transplantation","author":"Bagshaw E","year":"2017","unstructured":"Bagshaw E , CarottiA , BlackneyM , ChiariniV , PosthumusJ , KuessnerD . The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Italy: economic evaluation of the Phase III vital study and fungiscope matched case-control analysis . Presented at : 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation . Marseille, France , 26\u201329 March 2017 ."},{"key":"e_1_3_4_41_1","volume-title":"27th European Congress of Clinical Microbiology and Infectious Diseases","author":"Bagshaw E","year":"2017","unstructured":"Bagshaw E , BlackneyM , HeimannSMet al. The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Germany: economic evaluation of the Phase III VITAL study and FungiScope matched case-control analysis . Presented at : 27th European Congress of Clinical Microbiology and Infectious Diseases . Vienna, Austria , 22\u201325 April 2017 ."},{"key":"e_1_3_4_42_1","volume-title":"28th European Congress of Clinical Microbiology and Infectious Diseases","author":"Bagshaw E","year":"2018","unstructured":"Bagshaw E , SalaunB , BlackneyM , PosthumusJ , KuessnerD . The cost of treating invasive mould diseases with isavuconazole compared with liposomal amphotericin B followed by posaconazole in France . Presented at : 28th European Congress of Clinical Microbiology and Infectious Diseases . Madrid, Spain , 21\u201324 April 2018 ."},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0443-1"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2018-0119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:40:38Z","timestamp":1719124838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2018-0119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.2217\/fmb-2018-0119"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2018-0119","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}